Research location
Chernihiv
Chernihiv Oblast, Ukraine
Advertisement
Research activity in Chernihiv
Chernihiv Oblast, UkraineCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Chernihiv
9 linked trials · page 1 of 1A Study of SPY072 in Rheumatic DiseaseNCT07148414 · 2025-08-21 · 1 site observation
ACTIVE_NOT_RECRUITING
CASI-Plus mHealth for Ukraine's APS Program (Aim 2)NCT05826977 · 2024-08-07 · 1 site observation
COMPLETED
CASI-Plus mHealth for Ukraine's APS Program (Aim 1)NCT06971120 · 2023-05-24 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).NCT04949256 · 2021-07-28 · 1 site observation
TERMINATED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)NCT04738487 · 2021-04-07 · 1 site observation
TERMINATED
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)NCT04704219 · 2021-02-23 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · 2021-01-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)NCT04191135 · 2019-12-19 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.